This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Revival of Stem Cells in Addison's Study (RoSA)

This study has been completed.
Information provided by (Responsible Party):
SHS Pearce, Newcastle University Identifier:
First received: March 9, 2011
Last updated: February 5, 2013
Last verified: February 2013
Autoimmune Addison's disease (AAD) is a rare and debilitating disease in which an autoimmune attack progressively destroys the adrenal cortex. Untreated it is universally fatal and treated people are absolutely dependent upon steroid medications lifelong, with a consequent excess in morbidity and mortality. A key feature of the adrenal cortex is that its cells are responsive to changes in circulating adrenocorticotrophic hormone (ACTH) concentration. This study aims to regenerate adrenocortical steroidogenic cell function in patients with established autoimmune Addison's disease (AAD) by stimulating proliferation and differentiation of their progenitor cells, the adrenocortical stem cells (ACSCs) (1,2). Using daily subcutaneous ACTH, administered according to two different regimens over 20 weeks, we will investigate whether regeneration of adrenal steroidogenic function through revival of ACSC activity is a realistic possibility.

Condition Intervention Phase
Adrenal Failure Drug: depot tetracosactide Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Revival of Autochthonous Adrenocortical Stem Cells in Autoimmune Addison's Disease

Resource links provided by NLM:

Further study details as provided by SHS Pearce, Newcastle University:

Primary Outcome Measures:
  • Peak serum Cortisol following ACTH stimulation [ Time Frame: Tested at 20 weeks ]

Secondary Outcome Measures:
  • Change in QoL [ Time Frame: 20 weeks ]

Enrollment: 13
Study Start Date: September 2010
Study Completion Date: September 2012
Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Synacthen
active treatment
Drug: depot tetracosactide
1mg, 3x weekly by sc injection


Ages Eligible for Study:   16 Years to 66 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Established autoimmune adrenal failure for >1yr age 16 to 65

Exclusion Criteria:

  • Significant cardio-respiratory, chronic renal or non-autoimmune liver disease; malignancy
  • Asthma, current infectious disease, recent live vaccination, acute psychosis, peptic ulcer disease
  • Pregnancy, breast feeding or plan for pregnancy within 9 months
  • Known non-autoimmune cause for adrenal failure (haemorrhage, adrenoleukodystrophy etc.)
  • Known hypersensitivity or allergy to Synacthen
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01371526

United Kingdom
Newcastle University
Newcastle upon Tyne, Tyne and Wear, United Kingdom, NE1 3BZ
Sponsors and Collaborators
Newcastle University
Principal Investigator: Simon H Pearce, MD Newcastle University
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: SHS Pearce, Professor of Endocrinology, Newcastle University Identifier: NCT01371526     History of Changes
Other Study ID Numbers: RoSAv1.2:04_10: R&D#5252
2009-018074-56 ( EudraCT Number )
Study First Received: March 9, 2011
Last Updated: February 5, 2013

Additional relevant MeSH terms:
Adrenal Insufficiency
Adrenal Gland Diseases
Endocrine System Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on September 21, 2017